Clinical Trials Browser

Phase 2/3 × NETWORK × 30 days × Clear all

NCT02438722 2026-05-18

S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer

Phase 2/3 Completed

174 enrolled 18 charts

Carcinoma, Non-Small-Cell Lung

NCT03851445 2026-05-18

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

Phase 2/3 Recruiting

10,000 enrolled

Previously Treated Non-Small Cell Lung Cancer

NCT05096663 2026-05-18

Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

Phase 2/3 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07001748 2026-05-15

STOPGAP II

Phase 2/3 Recruiting

Peritoneal Neoplasms

NCT06616584 2026-05-05

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

Phase 2/3 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms